Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,058 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: normal saline - intravenous Clear all
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm

NCT00873015
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Sodium nitrite, Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 2, 2026, 8:02 AM EDT
Recruiting Phase 3 Interventional

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

NCT06679855
View directory record Official record
Conditions
Post-ligation Cardiac Syndrome
Interventions
Milrinone infusion, Placebo infusion
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 3 Months
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma

NCT00843193
View directory record Official record
Conditions
Asthma
Interventions
INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

Sleep Intervention During Acute Lung Injury

NCT01050699
View directory record Official record
Conditions
Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Dexmedetomidine, Midazolam and Fentanyl
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 2, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Effect IV Ibuprofen and Inflammatory Responses

NCT01938040
View directory record Official record
Conditions
Gallbladder Disease
Interventions
ibuprofen, sugar water/placebo
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Newark, New Jersey • Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 2, 2026, 8:02 AM EDT
Not yet recruiting Not applicable Interventional

Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer

NCT07784855
View directory record Official record
Conditions
Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Oral Cavity
Interventions
Scheduled IV Hydration, Clinician Assessment-Based IV Hydration
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Bridgeport, West Virginia • Martinsburg, West Virginia • Morgantown, West Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas

NCT01904617
View directory record Official record
Conditions
Length of Labor, Second Stage of Labor, Intravenous Hydration of Labor
Interventions
Dextrose, Normal Saline
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3113593 in Participants With Chronic Kidney Disease

NCT02604160
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 2, 2026, 8:02 AM EDT
Terminated Phase 2 Interventional Results available

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

NCT04860518
View directory record Official record
Conditions
Covid19
Interventions
IFN beta-1a, Dexamethasone
Drug
Lead sponsor
Faron Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Newton, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 2, 2026, 8:02 AM EDT
Recruiting Phase 1 Interventional

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04689048
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Metastases, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 2, 2026, 8:02 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

NCT07214974
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
Behavioral · Device · Biological + 1 more
Lead sponsor
Noah Tech, Corp.
Industry
Eligibility
55 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palisades Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Not applicable Interventional Results available

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Ketamine, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain

NCT02372591
View directory record Official record
Conditions
Opioid-Related Disorders, Chronic Pain
Interventions
Buprenorphine, Hydromorphone, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 2, 2026, 8:02 AM EDT
Not listed Phase 2 Interventional

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

NCT02771509
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ANG-3777, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 2, 2026, 8:02 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RM1 Project 1 - tAN Naloxone

NCT05490134
View directory record Official record
Conditions
Analgesia
Interventions
Naloxone, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 2, 2026, 8:02 AM EDT
Suspended Phase 2 Interventional

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

NCT04482621
View directory record Official record
Conditions
COVID-19
Interventions
Decitabine, Placebo Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

NCT02989571
View directory record Official record
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 2, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

NCT00606502
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pralatrexate, Erlotinib, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 2, 2026, 8:02 AM EDT
Recruiting Phase 2 Interventional

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

NCT06721494
View directory record Official record
Conditions
Methamphetamine Intoxication, Methamphetamine Disorders, Methamphetamine Abuse
Interventions
Methamphetamine, Sterile Saline, CS-1103
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 2, 2026, 8:02 AM EDT